These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1225 related articles for article (PubMed ID: 32948057)

  • 1. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
    Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
    Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA Damage Repair Pathways in Pancreatic Adenocarcinoma.
    Das S; Cardin D
    Curr Treat Options Oncol; 2020 Jun; 21(8):62. PubMed ID: 32601814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
    Wattenberg MM; Asch D; Yu S; O'Dwyer PJ; Domchek SM; Nathanson KL; Rosen MA; Beatty GL; Siegelman ES; Reiss KA
    Br J Cancer; 2020 Feb; 122(3):333-339. PubMed ID: 31787751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
    Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    Moffat GT; O'Reilly EM
    Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting DNA damage repair pathways in pancreas cancer.
    Crowley F; Park W; O'Reilly EM
    Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance Olaparib for Germline
    Golan T; Hammel P; Reni M; Van Cutsem E; Macarulla T; Hall MJ; Park JO; Hochhauser D; Arnold D; Oh DY; Reinacher-Schick A; Tortora G; Algül H; O'Reilly EM; McGuinness D; Cui KY; Schlienger K; Locker GY; Kindler HL
    N Engl J Med; 2019 Jul; 381(4):317-327. PubMed ID: 31157963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
    Pishvaian MJ; Biankin AV; Bailey P; Chang DK; Laheru D; Wolfgang CL; Brody JR
    Br J Cancer; 2017 Apr; 116(8):1021-1026. PubMed ID: 28291774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
    Perkhofer L; Schmitt A; Romero Carrasco MC; Ihle M; Hampp S; Ruess DA; Hessmann E; Russell R; Lechel A; Azoitei N; Lin Q; Liebau S; Hohwieler M; Bohnenberger H; Lesina M; Algül H; Gieldon L; Schröck E; Gaedcke J; Wagner M; Wiesmüller L; Sipos B; Seufferlein T; Reinhardt HC; Frappart PO; Kleger A
    Cancer Res; 2017 Oct; 77(20):5576-5590. PubMed ID: 28790064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
    Li M; Mou Y; Hou S; Cao D; Li A
    Medicine (Baltimore); 2018 Nov; 97(45):e13113. PubMed ID: 30407325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.
    Gout J; Perkhofer L; Morawe M; Arnold F; Ihle M; Biber S; Lange S; Roger E; Kraus JM; Stifter K; Hahn SA; Zamperone A; Engleitner T; Müller M; Walter K; Rodriguez-Aznar E; Sainz B; Hermann PC; Hessmann E; Müller S; Azoitei N; Lechel A; Liebau S; Wagner M; Simeone DM; Kestler HA; Seufferlein T; Wiesmüller L; Rad R; Frappart PO; Kleger A
    Gut; 2021 Apr; 70(4):743-760. PubMed ID: 32873698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
    Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.
    Perkhofer L; Gout J; Roger E; Kude de Almeida F; Baptista Simões C; Wiesmüller L; Seufferlein T; Kleger A
    Gut; 2021 Mar; 70(3):606-617. PubMed ID: 32855305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.
    Miller AL; Fehling SC; Garcia PL; Gamblin TL; Council LN; van Waardenburg RCAM; Yang ES; Bradner JE; Yoon KJ
    EBioMedicine; 2019 Jun; 44():419-430. PubMed ID: 31126889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted PARP Inhibition Combined with FGFR1 Blockade is Synthetically Lethal to Malignant Cells in Patients with Pancreatic Cancer.
    Lai SW; Bamodu OA; Chen JH; Wu AT; Lee WH; Chao TY; Yeh CT
    Cells; 2020 Apr; 9(4):. PubMed ID: 32276472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP Inhibitor Sensitizes
    Kim C; Kim D; Lee DS; Lee S; Yoo C; Kim KP
    Anticancer Res; 2023 Dec; 43(12):5523-5534. PubMed ID: 38030179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
    Meijer LL; Garajová I; Caparello C; Le Large TYS; Frampton AE; Vasile E; Funel N; Kazemier G; Giovannetti E
    Ann Surg; 2020 Jun; 271(6):1137-1147. PubMed ID: 30394883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
    Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 62.